Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOURISH: Ad5.hAC6 in HFrEF
NCT03360448Phase 3Withdrawn
- Sponsor
- Renova Therapeutics
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
01
Overview
A Phase 3 trial of RT-100 in heart failure with reduced ejection fraction (HFrEF), sponsored by Renova Therapeutics. Planned start Jun 2019; status: withdrawn.
02
Drugs
RT-100
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03360448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03360448.